Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/7/13 → 05/10/17 |
Funding
- Novartis Pharmaceuticals Corporation: $6,375.00
Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib
- Schuster, Michael (PI)
- Gabig, Theodore (CoPI)
- Lan, Fengshuo (CoPI)
- Wood, Sylvia K (CoPI)
- Kiner-Strachan, Bonnie (CoPI)
- Masood, Aisha (CoPI)
Project: Research